Loading quotes...

Forecast

There is no analyst data available for this company.

News Go to news feed

Earnings plunge drives CSPC Pharmaceutical share to 52-week low

CSPC Pharmaceutical reported Q1 2026 revenue of RMB 6.465 billion (-7.8% y/y) and profit attributable to shareholders of RMB 860 million (-41.8% y/y), sending the stock down as much as 5.4% and triggering an intraday low of HK$6.64 (52-week low). Management and analysts mainly attribute the profit slump to a high year-ago comparison base from licensing income and higher selling, general and administrative and R&D expenses. Macquarie cut its price target to HK$11.50, while Bernstein's rating ... » More on de.investing.com
CSPC Pharmaceutical receives FDA clearance for US trials of obesity drug JMT206

CSPC Pharmaceutical has received FDA approval to conduct clinical trials in the US with the recombinant human monoclonal antibody JMT206 (anti‑ActRIIA/IIB). The study targets weight management in people with obesity or overweight who have at least one weight‑related comorbidity; JMT206 is intended to increase muscle mass and reduce body fat. The move allows CSPC to further develop JMT206 in the growing market for obesity drugs. » More on de.investing.com
Madrigal Pharmaceuticals receives EU approval for MASH drug Rezdiffra

The European Commission has granted Madrigal Pharmaceuticals a conditional marketing authorization for Rezdiffra (resmetirom) to treat adults with non‑cirrhotic MASH and moderate to advanced liver fibrosis. Madrigal plans to launch the drug in Germany at the end of 2025. The company reported strong quarterly sales of Rezdiffra and also closed a global licensing agreement with the CSPC Pharmaceutical Group; analysts responded by raising their estimates. » More on de.investing.com

Historical dividends Dividends

All dividend metrics All metrics

In 2026, CSPC Pharmaceutical Group has already paid €0.0167 in dividends. The last payout was in July.

Financials

In the last quarter, CSPC Pharmaceutical Group had revenue of €2.37B and net profit of €775.24M

(EUR)	June 2026	YoY
Revenue	2.37B	-
Gross profit	1.8B	-
Net profit	775.24M	-
EBITDA	1.02B	-

Fundamentals

Metric	Value
Market capitalization	€12.84B
Number of shares	11.41B
52-week high/low	€1.24 - €0.84
Dividend yield	3.50%
Dividends TTM	€0.0322
Next dividend	€0.0205
Beta	0.73
P/E ratio	10.52
PEG ratio	0.11
P/B ratio	2.07
P/S ratio	2.53

Company profile

CSPC Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical products in the People's Republic of China, other Asian regions, the Americas, Europe, and internationally. The company operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. It provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson's disease; Duomeisu for lymphoma, multiple myeloma, ovarian and breast cancers, and other malignant tumors; Jinyouli to prevent leucopenia and infection induced by chemotherapy; and Keaili for breast cancer. The company also offers Shuluoke, Nuomoling, Weihong, and Xinweihong for various infections; Xuanning for hypertension; Encun to prevent atherosclerotic thrombosis events; Qixiao to treat upper respiratory tract infection; Linmeixin and Shuanglexin for diabetes; Gubang and Gubangjia to treat osteoporosis in postmenopausal women; and Gaoshunsong for arthritis, osteoarthritis, ankylosing spondylitis, frozen shoulder, bursuitis, tenosynovitis, acute gout, dysmenorrhea, toothache and postoperative pain, low back pain, sprain, strain, and other soft tissue injuries. In addition, it provides Debixin for various ulcer; Qimaite for acute and chronic pains; antibiotics, vitamin C, and caffeine APIs; functional food and glucose products; and healthcare services. The company was formerly known as China Pharmaceutical Group Limited and changed its name to CSPC Pharmaceutical Group Limited in March 2013. CSPC Pharmaceutical Group Limited was incorporated in 1992 and is headquartered in Shijiazhuang, the People's Republic of China.

Name	CSPC Pharmaceutical Group
CEO	Lei Cai
Headquarters	Shijiazhuang, he Hong Kong
Website	cspc.com.hk
Sector	Health Care
Industry	Pharmaceuticals
IPO	05/13/2003
Employees	19,700